Oophorectomy and risk of primary liver cancer and fatty liver disease among women in the UK Clinical Practice Research Datalink

Date of Approval
Application Number
16_182
Technical Summary

We aim to conduct two case-control studies to assess the association between oophorectomy and the subsequent development of liver cancer or non-alcoholic fatty liver disease (NAFLD) among individuals in the CPRD. We also propose to include alcoholic fatty liver disease (ALFD) as a comparator group for NAFLD, as the aetiologies underlying these two types of liver disease differ. We will identify all eligible primary liver cancer and fatty liver disease cases in this population, and controls will be matched to cases at a 4:1 ratio on age, sex, general practice, and length of time in the CPRD. Oophorectomy will be classified as ever oophorectomy and bilateral oophorectomy. We will additionally classify oophorectomy by duration of time between oophorectomy and outcome. We will use conditional logistic regression to assess crude and adjusted risk estimates (odds ratios [ORs] and 95% confidence intervals [CIs]) for oophorectomy and the risk of liver cancer or fatty liver disease, subclassified as NAFLD or AFLD. In addition to variables controlled through matching, a comprehensive list of potential confounders will be evaluated.

Health Outcomes to be Measured

Primary liver cancer or fatty liver disease, including the subtypes of NAFLD and AFLD

Collaborators

Katherine McGlynn - Chief Investigator - National Institutes of Health - USA
Baiyu Yang - Collaborator - Roche
Barry I Graubard - Collaborator - National Cancer Institute ( NCI )
Jessica Petrick - Collaborator - National Cancer Institute ( NCI )